Expired activity
Please go to the PowerPak homepage and select a course.

Management of Long-Chain Fatty Acid Oxidation Disorder: Pharmacist, Provider and Patient Perspectives (Webinar Archive)

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Ultragenyx Pharmaceutical, Inc.


Richard J. Faris, PhD, MSc, RPh
Senior Vice President and Head of Pharmacy
PANTHERx Rare Pharmacy
Pittsburgh, PA


Nicola Longo, MD, PhD
Professor of Pediatrics and Chief
Division of Medical Genetics, Department of Pediatrics
Medical Genetics/Pediatrics
University of Utah
Salt Lake City UT

Tasia Rechisky
Malden, MA


Dr. Faris has disclosed that he is an employee of PANTHERx Rare Pharmacy.

Dr. Longo has disclosed that he has served as a consultant and clinical investigator for Reneo Pharmaceuticals and Ultragenyx Pharmaceutical Inc.

Ms. Rechisky has disclosed that she has served as a consultant for the Ultragenyx Pateint Leadership Council.

The clinical reviewer, Daphne Davis, PharmD, BCOP has no actual or potential conflicts of interest in relation to this program.

Susanne Batesko, RN, BSN, Kim Miniter, MSEd, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.


acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-20-013-H01-P
Credits: 1.5 hour (0.15 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 90 minutes


May 11, 2020


May 11, 2021


This accredited activity has been designed for specialty pharmacists who are involved in the care of patients with long-chain fatty-acid oxidation disorder.


During the period May 11, 2020 to May 11, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


To provide specialty pharmacists with education on the management of long-chain fatty acid oxidation disorder (LCFAOD).


Upon completion of this activity, participants will be able to:

  • Identify the signs and symptoms of LCFAOD
  • Design an appropriate diet for a patient with LCFAOD
  • Describe current treatments for LCFAOD
  • Explain the potential role of triheptanoin and other emerging treatments for LCFAOD
  • Describe the role of specialty pharmacy in rare diseases

Additional References

» Slide (PDF) | » FAOD Web Resources (PDF)


Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer:

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or Ultragenyx Pharmaceutical, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.